Cargando…

Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance)

BACKGROUND: How can a clinician and patient incorporate survival and toxicity information into a single expression of comparative treatment benefit? Sloan et al. recently extended the ½ standard deviation concept for judging the clinical importance of findings from clinical trials to survival and tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Major-Elechi, Brittny T., Novotny, Paul J., Singh, Jasvinder A., Bonner, James A., Dueck, Amylou C., Sargent, Daniel J., Grothey, Axel, Sloan, Jeff A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686677/ https://www.ncbi.nlm.nih.gov/pubmed/31396297 http://dx.doi.org/10.6000/1929-6029.2018.07.04.4

Ejemplares similares

Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance)
por: Sideras, Kostandinos, et al.
Publicado: (2022)

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial
por: Cheng, H, et al.
Publicado: (2014)

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
por: Chumsri, Saranya, et al.
Publicado: (2022)

Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance)
por: Boora, Ganesh K., et al.
Publicado: (2016)

Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG‐N0377, Alliance)
por: Vera Aguilera, Jesus, et al.
Publicado: (2018)

A novel approach of longitudinal adverse event evaluation in oncology clinical trials: the Toxicity over Time (ToxT) analysis of clinical trials N9741 and 979254 (Alliance)
por: Thanarajasingam, Gita, et al.
Publicado: (2016)

BRAF V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance)
por: Slostad, Jessica A., et al.
Publicado: (2021)

Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
por: Pogue-Geile, Katherine L, et al.
Publicado: (2020)

Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study
por: Adjei, Araba A., et al.
Publicado: (2021)

Results of NCCTG N0275 (Alliance) – a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma
por: Rule, William G., et al.
Publicado: (2016)

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
por: Perez, Edith A., et al.
Publicado: (2013)

Correction to: Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
por: Lee, Minji K., et al.
Publicado: (2021)

Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
por: Lee, Minji K., et al.
Publicado: (2020)

Correction to: Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
por: Lee, Minji K., et al.
Publicado: (2023)

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)
por: Witzig, T E, et al.
Publicado: (2017)

Score equivalence of paper-, tablet-, and interactive voice response system-based versions of PROMIS, PRO-CTCAE, and numerical rating scales among cancer patients
por: Lee, Minji K., et al.
Publicado: (2021)

Identifying meaningful change on PROMIS short forms in cancer patients: a comparison of item response theory and classic test theory frameworks
por: Lee, Minji K., et al.
Publicado: (2022)

EXM 89-20
por: Daems, G
Publicado: (1989)

Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future
por: Sargent, Daniel, et al.
Publicado: (2010)

The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD
por: Pacyna, Joel E., et al.
Publicado: (2018)

Characterization of Nonphysician Health Care Workers’ Burnout and Subsequent Changes in Work Effort
por: Dyrbye, Liselotte N., et al.
Publicado: (2021)

Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes
por: Sprangers, Mirjam A. G., et al.
Publicado: (2010)

Patient-reported quality-of-life outcomes in relation to provider-assessed adverse events during head and neck radiotherapy
por: Niska, Joshua R., et al.
Publicado: (2020)

Systemic Therapy for Elderly Patients with Gastrointestinal Cancer
por: Hubbard, Joleen M., et al.
Publicado: (2011)

25. EFFECT OF STEREOTACTIC RADIOSURGERY COMPARED TO WHOLE-BRAIN RADIOTHERAPY FOR LIMITED BRAIN METASTASIS ON LONG TERM COGNITION AND QUALITY OF LIFE: A POOLED ANALYSIS OF NCCTG N107C/CEC.3 AND N0574 (ALLIANCE) RANDOMIZED CLINICAL TRIALS
por: Palmer, Joshua, et al.
Publicado: (2020)

Population‐level evidence of survival benefits of patient‐reported outcome symptom monitoring software systems in routine cancer care
por: Basch, Ethan, et al.
Publicado: (2020)

Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2
por: Mazza, Gina L., et al.
Publicado: (2021)

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)
por: Singh, Preet Paul, et al.
Publicado: (2016)

Correction to: Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2
por: Mazza, Gina L., et al.
Publicado: (2021)

Minutes of Mini-Vertex meeting held on 20 1 89
por: Triggiani, G
Publicado: (1989)

Public feedback on a proposed statewide virtual translational research community
por: Eder, Milton (Mickey), et al.
Publicado: (2019)

Using Garden Cafés to engage community stakeholders in health research
por: Balls-Berry, Joyce E., et al.
Publicado: (2018)

The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831
por: Perez, Edith A., et al.
Publicado: (2015)

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
por: Geyer, Holly L., et al.
Publicado: (2015)

Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia
por: Tremblay, Douglas, et al.
Publicado: (2021)

ALEPH Mini Vertex: Minutes of the meeting held on 20 10 89
por: Moser, G
Publicado: (1989)

A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncology
por: Warsame, Rahma, et al.
Publicado: (2022)

Successes and lessons learned in database development for national multi-site cancer care delivery research trials: the Alliance for Clinical Trials in Oncology experience
por: Zahrieh, David, et al.
Publicado: (2022)

Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease
por: Taarnhøj, Gry A., et al.
Publicado: (2020)

POC20 Compte-rendu de la réunion du 13-06-89
por: Canard, B, et al.
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_ho2eouvkbpo8sjti29okqu8rkc